{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:54:13Z","timestamp":1793386453694,"version":"4.5.0"},"reference-count":32,"publisher":"Media Sphere Publishing House","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:p>Mexidol (ethylmethylhydroxypyridine succinate) is a modern neurometabolic medication increasingly being used in neuropediatrics. The results of recent studies confirming the positive effects of Mexidol pharmacotherapy in children with attention deficit hyperactivity disorder (ADHD), perinatal damages of the central nervous system (hypoxic-ischemic encephalopathy) and their consequences, neurological disorders and neurodevelopmental delay after surgery for congenital heart defects, neuroinfections (meningitis, encephalitis), posttraumatic epilepsy. Taking into account the unique multimodal action of Mexidol, it seems promising to expand the range of indications for its application in neuropediatrics, based on the results of new clinical trials organized in accordance with modern principles of evidence-based medicine.<\/jats:p>","DOI":"10.17116\/jnevro202312309243","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T13:20:41Z","timestamp":1699536041000},"page":"43","source":"Crossref","is-referenced-by-count":5,"special_numbering":"Vyp. 2","title":["The possibilities of Mexidol usage in neuropediatrics"],"prefix":"10.17116","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-7422","authenticated-orcid":false,"given":"N.N.","family":"Zavadenko","sequence":"first","affiliation":[{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-7398","authenticated-orcid":false,"given":"N.Yu.","family":"Suvorinova","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3856-1618","authenticated-orcid":false,"given":"A.N.","family":"Zavadenko","sequence":"additional","affiliation":[{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202312309243-1","unstructured":"Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-2","unstructured":"Voronina T.A. Pioneer of antioxidant neuroprotection. 20 years in clinical practice. RMJ. 2016;24(7):434-438. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-3","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201811812287"},{"key":"key-10.17116\/jnevro202312309243-4","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171173255-65"},{"key":"key-10.17116\/jnevro202312309243-5","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20211211117"},{"key":"key-10.17116\/jnevro202312309243-6","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2021121091145"},{"key":"key-10.17116\/jnevro202312309243-7","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212211273"},{"key":"key-10.17116\/jnevro202312309243-8","unstructured":"Clinical recommendations for the management of children with the consequences of perinatal damage to the central nervous system with diffuse muscular hypotony. Approved at the meeting of the Executive Committee of the Professional Association of Pediatricians of the Union of Pediatricians of Russia at the All-Russian Scientific and Practical Conference \u00abPharmacotherapy and Dietetics in Pediatrics\u00bb on September 28, 2013. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-9","unstructured":"The standard of specialized medical care for children with tick-borne viral encephalitis of severe severity. Order of the Ministry of Health of the Russian Federation No. 1425n dated December 24, 2012. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-10","unstructured":"Clinical recommendations (treatment protocol) \u00abProviding medical care to children with meningococcal infection\u00bb. FMBA of Russia. Public organization \u00abEurasian Society for Infectious Diseases\u00bb. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-11","unstructured":"The standard of specialized medical care for children with a generalized form of severe meningococcal infection. Order of the Ministry of Health of the Russian Federation No. 804n dated November 9, 2012. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-12","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212204175"},{"key":"key-10.17116\/jnevro202312309243-13","unstructured":"Potapova IS, Khromina NV, Protopopova MV. The course of school adaptation in children with attention deficit hyperactivity disorder on the background of Mexidol use. Bulletin of Experimental Biology and Medicine. 2006;S1:72-74. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-14","doi-asserted-by":"publisher","DOI":"10.1177\/1087054713510354"},{"key":"key-10.17116\/jnevro202312309243-15","doi-asserted-by":"publisher","DOI":"10.4103\/ijpvm.IJPVM_80_18"},{"key":"key-10.17116\/jnevro202312309243-16","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9111039"},{"key":"key-10.17116\/jnevro202312309243-17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25194440"},{"key":"key-10.17116\/jnevro202312309243-18","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9020176"},{"key":"key-10.17116\/jnevro202312309243-19","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6640206"},{"key":"key-10.17116\/jnevro202312309243-20","unstructured":"Levitina EV, Petrushina AD. Pathogenetic justification of the use of Mexidol in the treatment of hypoxic-ischemic encephalopathy in newborn children. Russian Pediatric Journal. 2001;6:4-8. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-21","unstructured":"Askerova DM. The use of Mexidol in newborns with intrauterine growth retardation in the correction of hypoxic-ischemic lesions of the central nervous system. The Successes of Modern Natural Science. 2011;5:50-52. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-22","unstructured":"Barkhatov MV, Bochkun-Zharikova AV, Viktorova GI, et al. The validity of the use of the drug Mexidol in children with the consequences of hypoxic perinatal encephalopathies. The first experience of using the medication Mexidol in pediatric practice. M. 2005:25-32. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-23","unstructured":"Zvonareva EV. Comparison of the effect of Mexidol and pantocalcin on the clinical and functional manifestations of posthypoxic encephalopathy in infants. Bulletin of Experimental Biology and Medicine. 2012;S1:237-239. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-24","unstructured":"Khayretdinova TB. The effectiveness of Mexidol in young children operated on for congenital heart defects at the stages of their rehabilitation. Bulletin of Experimental Biology and Medicine. 2012;S1:240-245. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-25","unstructured":"Kryuger EA, Bobrysheva AV, Mazinova ER, et al. Mexidol as corrector free-radical oxidation in the complex treatment of purulent meningitis in children. Crimean Journal of Experimental and Clinical Medicine. 2012;2(1-2):71-75. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-26","unstructured":"Alekseeva LA, Skripchenko NV, Bessonova TV. Laboratory criterion for endogenous intoxication in meningococcal infection in children. Pediatrician. 2011;2(2):8-13. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-27","unstructured":"Khvoynov DV, Velts AV, Akhmetova VM, Viktorov VV, Galeev FS. The use of Mexidol in intensive therapy of purulent neuroinfections in children. Bulletin of Experimental Biology and Medicine. 2012;S1:91-95. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-28","unstructured":"Tsypina LG. The use of Mexidol in the complex therapy of acute neuroinfections in children. Bulletin of Experimental Biology and Medicine. 2012;S1:246-252. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-29","unstructured":"Karavaeva MO, Kryuchkova EP. The use of Mexidol in focal forms of tick-borne encephalitis, chickenpox encephalitis and encephalitis with rubella in children in the intensive care unit and in the early recovery period. Bulletin of Experimental Biology and Medicine. 2006;S1:186-189. (In Russ.)"},{"key":"key-10.17116\/jnevro202312309243-30","doi-asserted-by":"publisher","DOI":"10.17749\/2077-8333.2016.8.1.075-082"},{"key":"key-10.17116\/jnevro202312309243-31","doi-asserted-by":"publisher","DOI":"10.17749\/2077-8333.2018.10.4.026-038"},{"key":"key-10.17116\/jnevro202312309243-32","unstructured":"Barkhatov MV, Nosyrev AV, Dekhtyar AV, Galaktionova MYu. The use of the drug Mexidol in the complex treatment of children with post-traumatic epilepsy. Bulletin of Experimental Biology and Medicine. 2006;S1:9-13. (In Russ.)"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T10:29:53Z","timestamp":1745490593000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2023\/9-2\/1199772982023092043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11,9]]}},"alternative-id":["10.17116\/jnevro202312309243"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202312309243","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}